Carrying value of deferred royalty obligations, net
912,536
905,336
891,388
868,059
Funding Agreement
15,709
19,281
21,439
30,029
Royalty Purchase Agreement
0
0
0
0
Fair value of embedded derivative liability
15,709
19,281
21,439
30,029
Unamortized debt discount and issuance costs
48,871
53,432
57,797
61,962
Deferred royalty obligations, net
879,374
871,185
855,030
836,126
Operating lease liabilities, net of current portion
14,973
14,216
3,811
3,427
Deferred revenue, net of current portion
10,424
11,776
13,080
13,131
Other long-term liabilities
240
229
244
679
Total liabilities
3,723,192
3,639,856
3,012,606
2,920,979
Redeemable convertible noncontrolling interests
-1,018
-951
-570
23
Common stock, 0.001 par value 500,000,000 shares authorized 198,759,831 shares issued and 192,633,286 shares outstanding as of june 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of december 31, 2025
206
204
202
200
Treasury stock, at cost 7,597,172 shares as of june 30, 2026 7,597,172 shares as of december 31, 2025
533,279
405,776
323,276
323,276
Additional paid-in capital
2,155,318
2,112,454
2,057,646
2,018,335
Accumulated other comprehensive income (loss)
-7
-8
12
2
Accumulated deficit
-4,137,453
-3,985,237
-3,821,194
-3,628,331
Total bridgebio stockholders deficit
-2,515,215
-2,278,363
-2,086,610
-1,933,070
Noncontrolling interests
10,340
10,439
10,599
10,318
Total stockholders deficit
-2,504,875
-2,267,924
-2,076,011
-1,922,752
Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit
1,217,299
1,370,981
936,025
998,250
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.